Durable Responses from Acalabrutinib in Combination with Rituximab, Cyclophosphamide, Doxorubicin, Vincristine and Prednisolone (R-CHOP) As First Line Therapy for Patients with Diffuse Large B-Cell Lymphoma (DLBCL): The Accept Phase Ib/II Single Arm Study

被引：2
|
作者：
Davies, Andrew J. [1 ,2 ]
Caddy, Josh [3 ]
McLaughlin, Katy [3 ]
Wignall, Christopher [3 ]
Waugh, Robert [3 ]
Collins, Graham P. [4 ]
Stanton, Louise [3 ]
Saunders, Geoff N. [3 ]
Cummin, Thomas [5 ]
Schuh, Anna [6 ]
Ardeshna, Kirit M. [7 ]
McMillan, Andrew K. [8 ]
Radford, John [9 ,10 ]
Lewis, David John [11 ]
Coleman, Adam R. [1 ]
Griffiths, Gareth [3 ]
Burton, Cathy [12 ]
Barrans, Sharon [12 ]
Johnson, Peter [1 ,13 ]
机构：
[1] Canc Res UK Expt Canc Med Ctr UK, Southampton, Hants, England
[2] Southampton Canc Res UK Ctr, Southampton, Hants, England
[3] Univ Southampton, Canc Res UK Southampton Clin Trials Unit, Southampton, Hants, England
[4] Churchill Hosp, Oxford Canc & Haematol Ctr, Oxford, England
[5] Portsmouth Hosp Univ NHS Trust, Portsmouth, Hants, England
[6] Univ Oxford, Oxford Mol Diagnost Ctr, Oxford, England
[7] Univ Coll London Hosp NHS Fdn Trust, Dept Haematol, London, England
[8] Nottingham Univ Hosp NHS Trust, Nottingham, England
[9] Univ Manchester, NIHR Clin Res Facil, Manchester, Lancs, England
[10] Christie NHS Fdn Trust, Manchester Acad Hlth Sci Ctr, Manchester, Lancs, England
[11] Derriford Hosp, Dept Haematol, Plymouth, Devon, England
[12] Leeds Canc Ctr, Haematol Malignancy Diagnost Serv, Leeds, W Yorkshire, England
[13] Univ Southampton, Fac Med, Sch Canc Sci, Southampton, Hants, England
来源：
BLOOD | 2022年 / 140卷
关键词：
D O I：
10.1182/blood-2022-163499
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：9478 / 9479
页数：2
相关论文
共 50 条
  • [1] Acalabrutinib in Combination with Rituximab, Cyclophosphamide, Doxorubicin, Vincristine and Prednisolone (R-CHOP) As First Line Therapy for Patients with Diffuse Large B-Cell Lymphoma (DLBCL): The Accept Phase Ib/II Single Arm Study
    Davies, Andrew
    Caddy, Josh
    Mercer, Katy
    Saunders, Geoff N.
    Stanton, Louise
    Collins, Graham P.
    Cummin, Thomas E. C.
    Schuh, Anna
    Ardeshna, Kirit M.
    McMillan, Andrew
    Radford, John A.
    Lewis, David John
    Coleman, Adam
    Griffiths, Gareth
    Burton, Cathy
    Barrans, Sharon
    Johnson, Peter
    BLOOD, 2020, 136
  • [2] ACCEPT: A phase Ib/II combination of acalabrutinib with rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone (R-CHOP) for patients with diffuse large B-cell lymphoma (DLBCL)
    Johnson, Peter W. M.
    Caddy, Joshua
    Cumin, Tom
    Merton, Bridgen
    Maishman, Tom
    Galanopoulou, Angelic
    Griffiths, Gareth
    Davies, Andrew
    CANCER RESEARCH, 2018, 78 (13)
  • [3] Rituximab in combination with cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) in diffuse large B-cell lymphoma
    Candelaria, Myrna
    Duenas-Gonzalez, Alfonso
    THERAPEUTIC ADVANCES IN HEMATOLOGY, 2021, 12
  • [4] OUTCOMES IN PATIENTS WITH PRIMARY GASTRIC DIFFUSE LARGE B-CELL LYMPHOMA AFTER RITUXIMAB, CYCLOPHOSPHAMIDE, DOXORUBICIN, VINCRISTINE AND PREDNISOLONE (R-CHOP) CHEMOTHERAPY
    Suh, C.
    Sohn, B. S.
    Yoon, D. H.
    Kim, S.
    Lee, D. H.
    Kim, S. W.
    Huh, J. R.
    Lee, J. S.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2009, 94 : 650 - 650
  • [5] Outcomes in patients with primary gastric diffuse large B-cell lymphoma after rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone (R-CHOP) chemotherapy
    Sohn, B.
    Yoon, D.
    Kim, S.
    Lee, D.
    Kim, S.
    Huh, J.
    Lee, J.
    Suh, C.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [6] Pharmacokinetic and pharmacodynamic evaluation of a biosimilar rituximab in newly diagnosed diffuse large B-cell lymphoma (DLBCL) treated with R-CHOP (rituximab, cyclophosphamide, adriamycin, vincristine, prednisolone)
    Viswabandya, Auto
    Prashanthi, P. V.
    Raju, C. Nirmala
    Rajsekhar, Reena
    Mathews, Vikram
    Madki, Shivkumar
    Abhayankar, Dhiraj
    Kethireddypally, Rukmini
    George, Biju
    Chandy, Mammen
    Reddy, Cartikeya
    Srivastava, Alok
    BLOOD, 2007, 110 (11) : 194B - 194B
  • [7] Zanubrutinib in Combination with Rituximab, Cyclophosphamide, Doxorubicin, Vincristine and Prednisone (R-CHOP) for Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL): Interim Results from a Phase 1b Clinical Trial
    Sawalha, Yazeed
    Welkie, Rina Li
    Krivenko, Anna
    Hess, Brian
    Sigmund, Audrey M.
    Voorhees, Timothy
    Hanel, Walter
    Bond, David A.
    Reneau, John C.
    Epperla, Narendranath
    Alinari, Lapo
    Brammer, Jonathan E.
    Christian, Beth
    Baiocchi, Robert
    Maddocks, Kami J.
    BLOOD, 2023, 142
  • [8] Venetoclax Plus Rituximab, Cyclophosphamide, Doxorubicin, Vincristine and Prednisolone (R-CHOP) Improves Outcomes in BCL2-Positive First-Line Diffuse Large B-Cell Lymphoma (DLBCL): First Safety, Efficacy and Biomarker Analyses from the Phase II CAVALLI Study
    Morschhauser, Franck
    Feugier, Pierre
    Flinn, Ian W.
    Gasiorowski, Robin E.
    Greil, Richard
    Illes, Arpad
    Johnson, Nathalie A.
    Larouche, Jean-Francois
    Lugtenburg, Pieternella J.
    Patti, Caterina
    Salles, Gilles
    Trneny, Marek
    de Vos, Sven
    Mir, Farheen
    Kornacker, Martin
    Punnoose, Elizabeth A.
    Samineni, Divya
    Szafer-Glusman, Edith
    Petrich, Adam
    Sinha, Arijit
    Mobasher, Mehrdad
    Zelenetz, Andrew D.
    BLOOD, 2018, 132
  • [9] Polatuzumab vedotin plus rituximab, cyclophosphamide, doxorubicin, and prednisone (pola-r-chp) versus rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone (r-chop) therapy in patients with previously untreated diffuse large b-cell lymphoma (dlbcl): results from the phase iii polarix study
    Dietrich, Sascha
    Tilly, Herve
    Morschhauser, Franck
    Sehn, Laurie H.
    Friedberg, Jonathan W.
    Trneny, Marek
    Sharman, Jeff
    Herbaux, Charles
    Burke, John M.
    Matasar, Matthew
    Rai, Shinya
    Izutsu, Koji
    Mehta-Shah, Neha
    Oberic, Lucie
    Chauchet, Adrien
    Jurczak, Wojciech
    Song, Yu Qin
    Greil, Richard
    Mykhalska, Larysa
    Bergua Burgues, Juan Miguel
    Cheung, Matthew C.
    Pinto, Antonio
    Shin, Ho-Jin
    Hapgood, Greg
    Munhoz, Eduardo
    Salles, Gilles
    ONCOLOGY RESEARCH AND TREATMENT, 2022, 45 (SUPPL 3) : 165 - 165
  • [10] Polatuzumab vedotin plus rituximab, cyclophosphamide, doxorubicin, and prednisone (Pola-R-CHP) compared with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) in patients with untreated diffuse large B-cell lymphoma (DLBCL): results of the phase III POLARIX study
    Dietrich, S.
    Tilly, H.
    Morschhauser, F.
    Sehn, L. H.
    Friedberg, J.
    Trneny, M.
    Sharman, J. P.
    Herbaux, C.
    Burke, J. M.
    Matasar, M.
    Rai, S.
    Izutsu, K.
    Mehta-Shah, N.
    Oberic, L.
    Chauchet, A.
    Jurczak, W.
    Song, Y.
    Greil, R.
    Mykhalska, L.
    Burgues, J. M. B.
    Cheung, M. C.
    Pinto, A.
    Shin, H-J
    Hapgood, G.
    Munhoz, E.
    Abrisqueta, P.
    Gau, J-P
    Hirata, J.
    Jiang, Y.
    Yan, M.
    Lee, C.
    Flowers, C.
    Salles, G.
    ONCOLOGY RESEARCH AND TREATMENT, 2022, 45 (SUPPL 2) : 193 - 194
12345